Semi-structured interview guide.

<p>Semi-structured interview guide.</p

Dimensions of participants’ representations of generic medication: identity of the generic, issues related to the risks, and costs (S1 Text).

<p>Dimensions of participants’ representations of generic medication: identity of the generic, issues related to the risks, and costs (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0134661#pone.0134661.s001" target="_blank">S1 Text</a>).</p

Sociodemographic characteristics of the participants (S1 Table).

<p>Sociodemographic characteristics of the participants (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0134661#pone.0134661.s002" target="_blank">S1 Table</a>).</p

Results of the ANOVA analyses on all the tests.

<p>The table shows the results for the main, the peak value and the subgroup analysis. The main analysis was performed on all subjects for all data. The peak value analysis included only the basal values and the maximal effect before administration of flumazenil. The subgroup analysis included the subjects with peak plasma levels of clobazam before administration of flumazenil and plasma concentrations of at least 200 µg/ml during the same period (n = 8). The table shows the p values for the interaction of drug with time and for the factors drug and time. For analyses with a significant interaction, the results of the effects of the factors drug and time are not interpretable and are therefore not presented (marked as n/p).</p>*<p>: P-Values <0.05. VAS: pain intensity as assessed by the visual analog scale (0  =  no pain, 10  =  worst pain imaginable). AUC: area under the curve. DSST: digit symbol substitution test (measure of psychomotor performance). n/a: not applicable. n/p: not presented.</p

Experimental pain tests employed.

<p>Experimental pain tests employed.</p

Pharmacokinetic parameters of clobazam.

<p>The table reports the parameters in all volunteers and in the subgroup that included the subjects with peak plasma levels of clobazam below 180 minutes and plasma concentrations of at least 200 µg/ml during the same period (n = 8). Data are expressed as mean values (SD).</p

Time plan of the experiment.

<p>Horizontal arrow: Testing time; ZZ: Resting time; EX: Medical examination, installation of the testing equipment and training measures; CT: Measures on the area of capsaicin hyperalgesia; ET: Cutaneous electrical stimulation; ED: Intramuscular electrical stimulation, pressure stimulation, cold pressor test, conditioned pain modulation and cuff algometry; BT: Psychomotor performance test; b: Blood sample.</p

Results of the pain tests performed.

<p>The data are expressed as mean (SD). Statistical significance is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0043896#pone-0043896-t003" target="_blank">table 3</a>.</p><p>n/a: not applicable. AUC: area under the curve. VAS: visual analog scale for pain (range 0–10).</p

Flowchart of the study.

<p>Flowchart of the study.</p

Static pinprick hyperalgesia after capsaicin.

<p>The area of static hyperalgesia significantly increased with the active placebo tolterodine (p<0.001), but not with clobazam and clonazepam.</p